New drug combo shows promise in wiping out breast cancer before surgery
NCT ID NCT04290793
First seen Jan 10, 2026 · Last updated May 08, 2026 · Updated 15 times
Summary
This study tests whether adding the drug pyrotinib to standard chemotherapy before surgery can completely eliminate HER2-positive early breast cancer in 113 women. Participants receive a combination of drugs, then surgery, and are followed for cancer recurrence. The goal is to see if this approach improves the chance of having no cancer left at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Conditions
Explore the condition pages connected to this study.